Literature DB >> 30255751

Preeclampsia - Current Management and Future Approach.

Weronika Dymara-Konopka1, Marzena Laskowska1, Jan Oleszczuk1.   

Abstract

Preeclampsia is one of the most serious pregnancy - specific medical conditions of increasing incidence. It remains a major cause of maternal and fetal morbidity and mortality. Although maternal mortality is especially high in developing countries, preeclampsia and its complications are one of the top four causes of maternal deaths even in developed societies. Unfortunately, yet the only effective and definitive treatment of preeclampsia is delivery of the baby and placenta, and its time depends on the disease severity and gestational age. In this review, we report principles of management of preeclampsia in the light of current international recommendations. Suggested failure of the placental development and significant role of angiogenic factors and their receptors in etiology of preeclampsia give the possibility for their future use in diagnosis and risk assessment of the disease and open new chapter of possible solutions also in the field of treatment of this serious pregnancy complication. Introduction of an advanced form of therapy that could safely prolong the duration of pregnancy would be invaluable in the area of preeclampsia management and lowering perinatal complications, especially in women with early-onset severe preeclampsia. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Pregnancy; angiogenic factors; hypertension; management; preeclampsia; treatment.

Mesh:

Substances:

Year:  2018        PMID: 30255751     DOI: 10.2174/1389201019666180925120109

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  7 in total

1.  Prediction of Differentially Expressed Genes and a Diagnostic Signature of Preeclampsia via Integrated Bioinformatics Analysis.

Authors:  Shan Huang; Shuangming Cai; Huibin Li; Wenni Zhang; Huanshun Xiao; Danfeng Yu; Xuan Zhong; Pei Tao; Yiping Luo
Journal:  Dis Markers       Date:  2022-06-07       Impact factor: 3.464

2.  Circulating endocan and preeclampsia: a meta-analysis.

Authors:  Xia Lan; Zhaoming Liu
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

3.  Tianma Gouteng Decoction Exerts Pregnancy-Protective Effects Against Preeclampsia via Regulation of Oxidative Stress and NO Signaling.

Authors:  Meiyuan Jin; Bin Cao; Chao Lin; Jiayong Li; Qiang Xu; Qianlei Ren; Shouying Xu; Chao Tang
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

4.  Integrated Analysis Identifies Four Genes as Novel Diagnostic Biomarkers Which Correlate with Immune Infiltration in Preeclampsia.

Authors:  Mu-Yi Yang; Ming-Hui Ji; Tian Shen; Lei Lei
Journal:  J Immunol Res       Date:  2022-04-28       Impact factor: 4.493

5.  Blood biomarkers representing maternal-fetal interface tissues used to predict early-and late-onset preeclampsia but not COVID-19 infection.

Authors:  Herdiantri Sufriyana; Hotimah Masdan Salim; Akbar Reza Muhammad; Yu-Wei Wu; Emily Chia-Yu Su
Journal:  Comput Struct Biotechnol J       Date:  2022-08-08       Impact factor: 6.155

6.  Up-regulation of microRNA-135 or silencing of PCSK6 attenuates inflammatory response in preeclampsia by restricting NLRP3 inflammasome.

Authors:  Xiaolan Zhao; Xun Zhang; Zhao Wu; Jie Mei; Lingling Li; Yujue Wang
Journal:  Mol Med       Date:  2021-07-23       Impact factor: 6.354

Review 7.  Differences in epidemiology of patients with preeclampsia between China and the US (Review).

Authors:  Ping Shi; Lei Zhao; Sha Yu; Jun Zhou; Jing Li; Ning Zhang; Baoxiang Xing; Xuena Cui; Shengmei Yang
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.